Last reviewed · How we verify
sucrose 24% oral solution
Sucrose 24% oral solution provides a concentrated source of glucose and fructose to increase blood sugar and caloric intake.
Sucrose 24% oral solution provides a concentrated source of glucose and fructose to increase blood sugar and caloric intake. Used for Hypoglycemia management in pediatric patients, Caloric and carbohydrate supplementation.
At a glance
| Generic name | sucrose 24% oral solution |
|---|---|
| Also known as | Oral sucrose solution, atropine |
| Sponsor | Children's Hospital of Michigan |
| Modality | Small molecule |
| Therapeutic area | Nutrition/Metabolic Support |
| Phase | FDA-approved |
Mechanism of action
Sucrose is a disaccharide that is rapidly hydrolyzed by intestinal enzymes into glucose and fructose, which are absorbed and increase blood glucose levels. This formulation is used as a simple carbohydrate source for rapid energy provision and caloric supplementation, particularly in pediatric patients who may be hypoglycemic or require nutritional support.
Approved indications
- Hypoglycemia management in pediatric patients
- Caloric and carbohydrate supplementation
Common side effects
- Hyperglycemia
- Gastrointestinal upset
- Osmotic diarrhea
Key clinical trials
- Be Sweet to Babies During Nasolaryngoscopy (NA)
- Intranasal Fentanyl in Preterm Infants Undergoing Peripherally Inserted Central Catheter Placement (PHASE3)
- Non-Pharmacological Nursing Pain Management for Preterm Infants (NA)
- Effectiveness of Oral Sucrose During Lung Ultrasound (NA)
- The Role of Time Interval Elimination on Pain Control of Preterm Infants by Sucrose Administration (NA)
- Study on the Effects of Different Premedication for LISA on Stress and Cerebral Tissue Oxygenation in Preterm Infants (PHASE1)
- Pilot Study of Sucrose to Reduce Pain in Sick Babies (PHASE4)
- Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sucrose 24% oral solution CI brief — competitive landscape report
- sucrose 24% oral solution updates RSS · CI watch RSS
- Children's Hospital of Michigan portfolio CI